Ruth Andrew
Ruth Andrew | |
|---|---|
| Academic background | |
| Education | University of Strathclyde (PhD, BSc) Barrhead High School |
| Academic work | |
| Discipline | Pharmacist |
Sub-discipline | Steroid biochemistry and applied mass spectrometry |
| Institutions | University of Edinburgh |
Ruth Andrew is a Scottish academic pharmacist and scientist. She is currently the personal chair of pharmaceutical endocrinology at the University of Edinburgh, and she was awarded a Fellowship of the Royal Society of Edinburgh in 2026.
Early life and education
[edit]Andrew attended Barrhead High School. In 1985, she studied pharmacy at the University of Strathclyde, and graduated with a Bachelor of Science in 1989.[1] Upon graduation, Andrew attend the Royal Pharmaceutical Society of Great Britain and qualified to practice as a pharmacist.[2]
In 1990, Andrew went back to the University of Strathclyde and studied pharmaceutical chemistry. In 1994, she obtained a Doctor of Philosophy.[1][2]
Career
[edit]In 1994, Andrew became a lecturer at the University of Edinburgh.[1] In 1995, she joined the Society for Endocrinology.[3]
From June 2012 to August 2016, Andrew was an external examiner for the University of Bradford.[4] In 2015, she was appointed personal chair of pharmaceutical endocrinology at the University.[1]
In 2021, Andrew was elected as the general secretary of the Society for Endocrinology.[5] In 2024, she was appointed the editor-in-chief for the Journal of Endocrinology and the Journal of Molecular Endocrinology.[3] In 2026, Andrew was elected a Fellow of the Royal Society of Edinburgh, in the discipline of biomedical and cognitive sciences.[6]
Research
[edit]Andrew's research focus is on steroid hormone action in metabolic disease, and mass spectrometry innovations to understand steroid biochemistry and lipid biology.[5]
In April 2019, Andrew was a senior author of a study that looked into 55,000 men who were given 5α-Reductase inhibitors for prostate treatment.[7] Over an 11 year period, the study found out that there was an increase risk of developing type 2 diabetes when taking those inhibitors for treatment.[8][9]
To date, Andrew has authored or co-authored over 200 publications.[4]
Selected publications
[edit]- Andrew, R.; Watson, D. G.; Best, S. A.; Midgley, J. M.; Wenlong, H.; Petty, R. K. H. (November 1993). "The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls". Neurochemical Research. 18 (11): 1175–1177. doi:10.1007/BF00978370. ISSN 0364-3190. Retrieved 13 October 2026.
- Andrew, Ruth; Phillips, David I. W.; Walker, Brian R. (1 May 1998). "Obesity and Gender Influence Cortisol Secretion and Metabolism in Man". The Journal of Clinical Endocrinology and Metabolism. 83 (5). Oxford University Press: 1806. doi:10.1210/jcem.83.5.4951. ISSN 0021-972X. Retrieved 13 October 2026.
- Rask, Eva; Olsson, Tommy; Soderberg, Stefan; Andrew, Ruth; Livingstone, Dawn E. W.; Johnson, Owe; Walker, Brian R. (1 March 2001). "Tissue-Specific Dysregulation of Cortisol Metabolism in Human Obesity". The Journal of Clinical Endocrinology and Metabolism. 86 (3). Oxford University Press: 1418–1421. doi:10.1210/jcem.86.3.7453. ISSN 0021-972X. PMID 11238541. Retrieved 13 October 2026.
- Rask, Eva; Walker, Brian R.; Söderberg, Stefan; Livingstone, Dawn E. W.; Eliasson, Mats; Johnson, Owe; Andrew, Ruth; Olsson, Tommy (1 July 2002). "Tissue-Specific Changes in Peripheral Cortisol Metabolism in Obese Women: Increased Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 Activity". The Journal of Clinical Endocrinology & Metabolism. 87 (7): 3330–3336. doi:10.1210/jcem.87.7.8661. ISSN 0021-972X. Retrieved 13 October 2026.
- Brunner, E. J.; Hemingway, H.; Walker, B. R.; Page, M.; Clarke, P.; Juneja, M.; Shipley, M. J.; Kumari, M.; Andrew, R.; Seckl, J. R.; Papadopoulos, A.; Checkley, S.; Rumley, A.; Lowe, G. D. O.; Stansfeld, S. A.; Marmot, M. G. (19 November 2002). "Adrenocortical, Autonomic, and Inflammatory Causes of the Metabolic Syndrome: Nested Case-Control Study". Circulation. 106 (21). Lippincott Williams & Wilkins: 2659–2665. doi:10.1161/01.CIR.0000038364.26310.BD. ISSN 0009-7322.
- Boonen, Eva; Vervenne, Hilke; Meersseman, Philippe; Andrew, Ruth; Mortier, Leen; Declercq, Peter E.; Vanwijngaerden, Yoo-Mee; Spriet, Isabel; Wouters, Pieter J.; Vander Perre, Sarah; Langouche, Lies; Vanhorebeek, Ilse; Walker, Brian R.; Van den Berghe, Greet (18 April 2013). "Reduced Cortisol Metabolism during Critical Illness". New England Journal of Medicine. 368 (16). Massachusetts Medical Society: 1477–1488. doi:10.1056/NEJMoa1214969. ISSN 0028-4793. PMC 4413428. PMID 23506003.
References
[edit]- 1 2 3 4 "Ruth Andrew". University of Edinburgh. 19 June 2024. Archived from the original on 13 August 2026. Retrieved 13 October 2026.
- 1 2 "Ruth Andrew". ResearchGate. Retrieved 13 October 2026.
- 1 2 Jonas, Kim, ed. (2023). "Ruth Andrew on meeting your funding needs" (PDF). The Endocrinologist. No. 150. pp. 20–21. ISSN 0965-1128. Retrieved 13 October 2026.
- 1 2 "Ruth Andrew". University of Edinburgh. Retrieved 13 October 2026.
- 1 2 Simpson, Helen, ed. (2021). "Ruth Andrew, your new General Secretary" (PDF). The Endocrinologist. No. 142. p. 24. ISSN 0965-1128. Retrieved 13 October 2026.
- ↑ "Professor Ruth Andrew". Royal Society of Edinburgh. Retrieved 13 October 2026.
- ↑ "Prostate medicines linked to type 2 diabetes risk, study suggests". University College London. Retrieved 13 October 2026.
- ↑ Wei, Li; Lai, Edward Chia-Cheng; Kao-Yang, Yea-Huei; Walker, Brian R; MacDonald, Thomas M; Andrew, Ruth (10 April 2019). "Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study". The BMJ: l1204. doi:10.1136/bmj.l1204. ISSN 0959-8138. PMC 6456811. PMID 30971393.
{{cite journal}}: CS1 maint: article number as page number (link) - ↑ Vundla, Arthur (12 April 2019). "Diabetes link to prostate medicines". Daily Record. Factiva DRECRD0020190412ef4c0002q.